The phase 3 open-label, randomized NIAGARA trial was designed to evaluate the benefits of adding perioperative immunotherapy durvalumab to standard…
en_news
The 3rd Research Day for Patients’ Associations took place on 6 September, focusing on colorectal cancer patients. The day began…
On September 26, the second edition of the symposium “Emerging Leaders in Biomedicine” took place, hosted by the Vall d’Hebron…
For many cancer patients, clinical trials are a new opportunity for treatment, especially in cases where various therapies have been…
Presented at ESMO Congress 2024, results from the phase 1b CodeBreaK study in patients with KRAS G12C-mutated metastatic colorectal cancer…
The phase 2 multicenter TROPION-PanTumor study was designed to evaluate the efficacy of TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) as…
Advances driven by research have led to significant developments in better understanding the molecular taxonomy of cancer and therapeutic breakthroughs…
Presented today at the ESMO Congress 2024* by Maria Vieito, Medical Oncologist at the Vall d’Hebron University Hospital, CORE Phase…
Among the 518 women enrolled in the international POSITIVE clinical trial with hormone receptor-positive early breast cancer who temporarily interrupted…
Researchers from VHIO are participating in an international study led by IRB Barcelona that identifies five independent factors predicting cancer…
